Pfizer Inc. (NYSE:PFE) Shares Sold by London Co. of Virginia

London Co. of Virginia lessened its position in Pfizer Inc. (NYSE:PFE - Free Report) by 89.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 109,608 shares of the biopharmaceutical company's stock after selling 929,462 shares during the period. London Co. of Virginia's holdings in Pfizer were worth $2,908,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. PSI Advisors LLC boosted its holdings in shares of Pfizer by 1.4% during the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after purchasing an additional 385 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its stake in Pfizer by 1.0% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock worth $1,027,000 after buying an additional 391 shares during the last quarter. D Orazio & Associates Inc. grew its holdings in Pfizer by 5.5% in the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock valued at $200,000 after buying an additional 391 shares during the period. Lipe & Dalton lifted its holdings in shares of Pfizer by 17.7% during the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock worth $71,000 after acquiring an additional 400 shares during the period. Finally, Beam Wealth Advisors Inc. boosted its position in shares of Pfizer by 1.5% in the fourth quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company's stock worth $728,000 after acquiring an additional 401 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.06% of the company's stock.

Pfizer Stock Up 3.6%

NYSE PFE opened at $23.09 on Tuesday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The business has a 50 day moving average price of $23.96 and a two-hundred day moving average price of $25.48. The stock has a market cap of $131.25 billion, a PE ratio of 16.37, a P/E/G ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the prior year, the firm earned $0.82 earnings per share. The business's quarterly revenue was down 7.8% compared to the same quarter last year. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.45%. Pfizer's dividend payout ratio is presently 124.64%.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Cantor Fitzgerald assumed coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, UBS Group lifted their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, Pfizer presently has an average rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.